NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.96 -0.39 (-3.77 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$9.96
Today's Range$9.87 - $10.98
52-Week Range$4.30 - $11.49
Volume251,953 shs
Average Volume177,895 shs
Market Capitalization$220.18 million
P/E Ratio-3.83
Dividend YieldN/A
Beta0.78
REDHILL BIOPHAR/S logoRedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Debt-to-Equity RatioN/A
Current Ratio4.20
Quick Ratio4.14

Price-To-Earnings

Trailing P/E Ratio-3.83
Forward P/E Ratio-5.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.01 million
Price / Sales52.83
Cash FlowN/A
Price / CashN/A
Book Value$2.12 per share
Price / Book4.70

Profitability

EPS (Most Recent Fiscal Year)($2.60)
Net Income$-45,540,000.00
Net Margins-726.64%
Return on Equity-114.27%
Return on Assets-86.82%

Miscellaneous

Employees74
Outstanding Shares21,270,000
Market Cap$220.18

REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) released its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.50). The biotechnology company earned $2.45 million during the quarter, compared to analysts' expectations of $2.14 million. REDHILL BIOPHAR/S had a negative return on equity of 114.27% and a negative net margin of 726.64%. View REDHILL BIOPHAR/S's Earnings History.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for REDHILL BIOPHAR/S.

What price target have analysts set for RDHL?

6 Wall Street analysts have issued 12 month price targets for REDHILL BIOPHAR/S's stock. Their forecasts range from $18.00 to $36.00. On average, they anticipate REDHILL BIOPHAR/S's share price to reach $22.60 in the next year. This suggests a possible upside of 126.9% from the stock's current price. View Analyst Ratings for REDHILL BIOPHAR/S.

What is the consensus analysts' recommendation for REDHILL BIOPHAR/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about REDHILL BIOPHAR/S stock?

Here are some recent quotes from research analysts about REDHILL BIOPHAR/S stock:
  • 1. HC Wainwright analysts commented, "We are maintaining our Buy rating on RedHill and our 12- month price target of $36.00 per ADS based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and 2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%." (7/2/2018)
  • 2. According to Zacks Investment Research, "Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). " (5/12/2018)

Who are some of REDHILL BIOPHAR/S's key competitors?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the folowing people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 52)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 49)
  • Mr. Gilead Raday, Chief Operating Officer (Age 43)
  • Dr. Reza Fathi, Sr. VP of R&D (Age 63)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 42)

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

Press coverage about RDHL stock has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. REDHILL BIOPHAR/S earned a news impact score of 0.07 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $9.96.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $220.18 million and generates $4.01 million in revenue each year. The biotechnology company earns $-45,540,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. REDHILL BIOPHAR/S employs 74 workers across the globe.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131.


MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.